Latest Steps In FDA Homeopathy Policy Overhaul Prompt Trade Group Questions
Executive Summary
A revised draft introduces list of risk-based enforcement priorities but doesn't necessarily tighten FDA oversight of homeopathics manufacturing and marketing, say CHPA and AIH.
You may also be interested in...
All About Eye Drops: Warnings To Six Homeopathic And Two Allopathic Firms; Seven US, One Swiss
Common across warnings is all the firms, retailers as well as manufacturers, are marketing OTC eye drops with noncompliant claims, including “prevent or improve cataracts” and “temporarily alleviate blepharitis symptoms.” One also had GMP problems.
US Enforcement On COVID-19 Consumer Health Fraud Circles Back To Ayurvedic Products
Georgia firm promoted a product as interrupting “infection chain” of coronavirus. Total of fraudulent COVID-19 claims FDA’s found in consumer health space approaches 200.
US Appropriators Question FDA’s OTC Switch Process Overhaul, Homeopathic Market Oversight
Appropriations Committee’s report with Agriculture, Rural Development, FDA and Related Agencies FY2021 budget bill also reiterated concern about adding acetaminophen dosing information for children to OTC monograph. But its mentions of FDA initiative to expand ingredients available OTC and homeopathic market oversight were firsts.